Show simple item record

Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

dc.contributor.authorYildiz, Birol
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorKostek, Osman
dc.contributor.authorKarabulut, Senem
dc.contributor.authorSEZGİN GÖKSU, SEMA
dc.contributor.authorAlandag, Celal
dc.contributor.authorAkagunduz, Baran
dc.contributor.authorBilgetekin, Irem
dc.contributor.authorCaner, Burcu
dc.contributor.authorŞAHİN, AHMET BİLGEHAN
dc.contributor.authorKose, Fatih
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorGulmez, Ahmet
dc.contributor.authorDOĞAN, ENDER
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorGurbuz, Mustafa
dc.contributor.authorErgun, Yakup
dc.contributor.authorKARAAĞAÇ, MUSTAFA
dc.contributor.authorDemiray, Atike Gokcen
dc.contributor.authorTurker, Sema
dc.contributor.authorSakalar, Teoman
dc.contributor.authorOzkul, Ozlem
dc.contributor.authorTelli, Tugba Akin
dc.contributor.authorSahin, Suleyman
dc.contributor.authorKILIÇKAP, SAADETTİN
dc.contributor.authorBilici, Ahmet
dc.contributor.authorERDOĞAN, BÜLENT
dc.contributor.authorÇİÇİN, İRFAN
dc.contributor.authorTastekin, Didem
dc.date.accessioned2021-03-02T17:44:13Z
dc.date.available2021-03-02T17:44:13Z
dc.date.issued2020
dc.identifier.citationHacioglu M. B. , Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., Akagunduz B., Bilgetekin I., Caner B., ŞAHİN A. B. , et al., "Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey", JOURNAL OF BUON, cilt.25, sa.4, ss.1897-1903, 2020
dc.identifier.issn1107-0625
dc.identifier.otherav_724a9872-4129-470e-a25b-b7b33690ff51
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/4404
dc.description.abstractPurpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.titleEfficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
dc.typeMakale
dc.relation.journalJOURNAL OF BUON
dc.contributor.departmentTrakya Üniversitesi , ,
dc.identifier.volume25
dc.identifier.issue4
dc.identifier.startpage1897
dc.identifier.endpage1903
dc.contributor.firstauthorID2284608


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record